Scarica l'app Stockscreener
1.95
18.89%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ORGS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.80
Aprire:
$1.95
Volume 24 ore:
130
Relative Volume:
66.00
Capitalizzazione di mercato:
$N/A
Reddito:
$662.00K
Utile/perdita netta:
$-29.02M
Rapporto P/E:
-0.2294
EPS:
-8.5
Flusso di cassa netto:
$-12.54M
1 W Prestazione:
-18.89%
1M Prestazione:
-73.27%
6M Prestazione:
-76.19%
1 anno Prestazione:
-86.10%
Intervallo 1D:
$1.95
$1.95
Intervallo di 1 settimana:
$1.95
$1.95
Portata 52W:
$1.95
$1.95
Orgenesis Inc Stock (ORGS) Company Profile
Confronta ORGS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
1.95 | 0 | 662.00K | -29.02M | -12.54M | -8.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-12-20 | Iniziato | Dawson James | Buy |
Orgenesis Inc Borsa (ORGS) Ultime notizie
GLP-1 Receptor Agonist Market Exclusive Report with Detailed - openPR.com
Genital Warts Treatment Market Deep Research Report Highlights Key PlayersMerck & Co., Inc., Bausch Health - openPR.com
Orgenesis (NASDAQ:ORGS) Shares Down 5.5% – Time to Sell? - Defense World
GLP-1 Receptor Agonist Market Rising Demand and Growth Forecast - openPR.com
Regenerative Therapies Market in 2025-2032 Detailed Study - openPR.com
Orgenesis Delays Filing of Quarterly Report - TipRanks
Orgenesis Announces Stock Repurchase Plan Of Up To $10 Million - Reuters
GLP-1 Receptor Agonist Market Projected To Witness Substantial GRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pearl Hol - The Manila Times
Nasdaq Announces Delisting of Multiple Companies' Securities Including Alpine 4 Holdings, Inc. and Orgenesis Inc. - Nasdaq
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition... - The Globe and Mail
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pea - ADVFN
Press Release Distribution & PR Platform - ACCESS Newswire
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
ORGENESIS Earnings Preview: Recent $ORGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Orgenesis (NASDAQ:ORGS) Stock Price Up 3.1% – Here’s What Happened - Defense World
How can multimodal and modular cleanrooms satisfy all requirements? - European Pharmaceutical Manufacturer
Point-of-Care Cell and Gene Therapy Manufacturing Market Report 2025-2035Closed-System Bioreactors and AI Bioprocessing Set to Shape PoC Manufacturing by 2035ResearchAndMarkets.com - Bluefield Daily Telegraph
Orgenesis Delays 10-K Filing Amid Financial Challenges - TipRanks
Key Trend Shaping the Common Warts Market in 2025: Enhancing Treatment Efficacy Through Clinical Trials - WhaTech
ORGENESIS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Cell therapy weekly: US$286 million acquisition expands CAR-T manufacturing and commercialization - RegMedNet
Genital Warts Market Growth: Projected to Reach $2.57 Billion by 2029 with an Impressive 5.4% CAGR - WhaTech
Can This New Spinal Cord Treatment Technology Revolutionize a $7.5B Medical Market? - StockTitan
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Orgenesis Featured in Special Report on Curing Diabetes - ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 201829/04/2019 - ACCESS Newswire
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Stem Cell Therapy Market to Grow from $5.8 Billion in 2022 to $19.1 - openPR
Orgenesis Inc. Secures $5 Million Equity Investment, Moves Trading to OTCQXOrgenesis Inc. (NASDAQ: ORGS) recently entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, a Nevada limited liability company. As per the agre - Defense World
Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC) - Defense World
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - StockTitan
Regenerative Xenograft Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Orgenesis (NASDAQ:ORGS) Stock Price Down 13.1% – What’s Next? - Defense World
UBS Group Lowers YETI (NYSE:YETI) Price Target to $43.00 - Defense World
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Orgenesis announces director resignation By Investing.com - Investing.com Canada
Orgenesis announces director resignation - Investing.com
Stromal Vascular Fraction Market Growth Projections: Surpassing USD 280.1 Billion by 2034 - openPR
Critical Contrast: Orgenesis (NASDAQ:ORGS) vs. BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Viral Vector Production (Research-use) Market Size to Hit USD 7.62 Bn by 2034 - BioSpace
Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Opportunity Analysis and Forecast, 2024-2030 - openPR
Orgenesis Inc. sees insider transactions totaling $16,259 in sales By Investing.com - Investing.com India
Orgenesis Inc. sees insider transactions totaling $16,259 in sales - Investing.com
GLP-1 Receptor Agonist Market Overall Study Report 2024-2031 | - openPR
7 Companies Owned by Pfizer - Investopedia
Orgenesis Inc Azioni (ORGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Capitalizzazione:
|
Volume (24 ore):